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INTRODUCTION 
Thromboangiitis obliterans also commonly known as Buerger’s  (TAO) is a 
chronic, segmental, severe, inflammatory, non-atherosclerotic occlusive vascular disease 
involving all the medium-sized arteries and veins of the limbs characterized by 
thrombosis and recanalisation of the involved vessels (1, 2).                           
  Leo Buerger, an Austrian surgeon and pathologist, who worked in New York City 
at Mount Sinai hospital, gave the first accurate pathological description in 1908 (1) and 
since then the condition is referred to as Buerger’s disease commonly. 
Thromboangiitis Obliterans is prevalent worldwide, but the numbers are markedly  
different in different  geographic locations.  The highest incidence occurs in the Middle  
East and Far East.     
  Among all patients with peripheral arterial disease (PAD) the prevalence has been 
shown  to range from  0.5% to 80%  globally to 45% to 63% in India (3). 
The symptoms of TAO are related to decreased perfusion to the extremities, the 
lower limbs being much more commonly involved than the upper limbs. The disease 
often presents in a males before the age of 45 who smoke very heavily. The patients 
present with symptoms of claudication, migratory superficial thrombophlebitis, and 
Raynaud’s phenomenon and erythema. (4) The disease waxes and wanes and finally rest 
pain and digital gangrene may occur which progresses proximally, often necessitating 
limb amputation. 
  The exact etiology of TAO is unknown. Several hypotheses regarding the 
pathogenesis are postulated but a tobacco associated vasculopathy is most accepted (2, 5), 
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possibly due to hypersensitivity to tobacco antigens (6) and also an underlying genetic 
predisposition (3).  
  Complete cessation of smoking is the most important step in the treatment of this 
debilitating disease.  Often aspirin (salicylic acid) is prescribed to patients (3) and lumbar 
symphathectomy provides short term benefit. Approximately 43% of patients diagnosed 
with the condition but who continue to smoke are at risk to have a digit or extremity 
amputated (2).            
  Lipoprotein (a) or Lp (a) has been reported to have an association with 
atherosclerotic disease, especially coronary artery disease (7) stroke (8) and also 
peripheral arterial disease (PAD) (9). It is also observed to be elevated in cases of 
Buerger’s disease (10). The physical structure of lipoprotein (a) is extremely similar to 
that of plasminogen competing with it for its binding site, and reducing fibrinolysis (11). 
It also has a role in thrombogenesis and atherosclerosis. 
            Lipoprotein (a) levels are predominantly determined genetically an. 
Environmental factors, including the classical vascular risk factors seem to have a weak 
association as causative factors. There is a definite variation among populations with 
Asians having comparatively higher serum concentrations of Lipoprotein (a) when 
compared to the Western population (12). However, there are very limited studies 
specifically investigating Lp (a) TAO among Asians or any other population. There are 
only few reports of TAO with elevated levels of lipoprotein (a) (10, 13).  
         Niacin has been proven to have an effective role in reducing serum Lp (a) levels 
in coronary artery disease in a Caucasian population (14). The available lipid modifying 
drugs currently in the market have a negligible effect on lipoprotein (a) levels with the 
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exception of niacin. In TAO, it might be worthwhile to study the prevalence of 
lipoprotein (a) in such patients as it has a role in thrombogenesis. It may be hypothesized 
that if patients with TAO are found to have elevated Lp (a) levels, further trials may be 
designed to test the therapeutic efficiency of niacin in this subgroup of PAD especially as 
this drug is cheap and safe. Hence this study on “Prevalence of elevated lipoprotein (a) in 
diagnosed cases of Thromboangiitis Obliterans presenting in a tertiary care centre in 
South India” was conducted. 
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Aims and Objectives 
 
Aim 
 
To study the association between lipoprotein (a) levels and thromboangiitis obliterans. 
Objectives: 
 
1. To compare the levels of lipoprotein (a) in TAO to age and sex matched controls. 
2. To study the association between lipoprotein (a) levels and severity of disease in TAO. 
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Serum Lipoprotein (a) levels in Thromboangiitis Obliterans 
 
REVIEW OF LITERATURE 
                 
                Thromboangiitis obliterans, also commonly referred to as Buerger’s disease is a 
non-atherosclerotic inflammatory condition that most commonly involves the small and 
medium sized arteries and veins of the upper and lower limbs. (1, 2) 
 
History 
           Thromboangiitis Obliterans (TAO) was first reported by Felix von Winiwarter, an 
Austrian physician, a native of Vienna in 1879 in an article titled "A strange form of 
endarteritis and endophlebitis with gangrene of the feet”. He described a 57-year old male 
patient who had an unusual occlusion of the vessels of the lower limbs. He attributed it to 
tissue growth from intima and the name “endarteritis obliterans" was proposed. Three 
years earlier, bacteriologist Carl Friedlander referred to it as arteritis obliterans.  However 
Leo Buerger, an Austrian surgeon and pathologist, who worked  in New York City at 
Mount Sinai hospital, gave the first accurate pathological description from amputated 
limbs of 11 Jewish migrant patients and presented his paper on TAO in 1908.(1)  Based 
on the findings he deduced that acute inflammation of the vascular wall led to the 
formation of thrombus, which later, during its organization, resulted in intimal 
hyperplasia and hence called it “Thromboangiitis obliterans” to distinguish it from 
“arteriosclerosis obliterans”.(1) Later this disease was referred to as “Winiwarter–
Buerger” syndrome,  “Buerger’s disease” or “Thromboangiitis Obliterans”.    
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                              Buerger’s disease is one of the two main types of premature peripheral 
arterial disease (PAD) in patients who are not diabetic.  Peripheral arterial disease 
includes either peripheral arterial occlusive disease which is atherosclerotic in nature or 
TAO which is non-atherosclerotic in nature.  
 
Epidemiology 
                 Thromboangiitis Obliterans is prevalent all across the globe. But the maximum 
incidence occurs in the Middle East and Far East (3).  At the Mayo clinic in Rochester, 
USA, the percentage of diagnosed cases of Buerger’s disease reduced significantly from 
104.3 per 100,000 patients in 1947 to almost 12.6 per 100,000 patients in 1986. (15)  The 
prevalence of the condition in the general population in the country of Japan was 
estimated at 5/100,000 persons in the year 1985 (3) and it has also shown a decreasing 
trend (16).  The prevalence of the TAO among all the patients with peripheral arterial 
occlusive disease was found to be as low as 0.5 to 5.6% in Western Europe to as high as 
45 to 63% in India and 16 to 66% in Korea and Japan.   In a particular subset of people, 
the Ashkenazi Jews, it is seen in up to 80 percent of the patients with peripheral arterial 
disease (3). It is also seen with increased frequency in Eastern Anatolia, Turkey. (17) In 
India, in a report from Bangalore, the proportion of patients with TAO among those 
admitted with peripheral vascular disease decreased from 63.9% in 2001 to 37.2% in 
2005. (18) 
             Buerger’s disease is a condition which mainly affects young males who smoker 
heavily. Earlier, they represented over 90% of affected patients, but later, in the 1980s 
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women have constituted an increasing percentage of the diagnosed cases. (> 20% in some 
studies) (5).  
 
 
Etiology & Pathogenesis 
 
 
Smoking 
The etiology of Buerger’s disease remains evasive, but the disease is known to have a 
strong link with tobacco consumption and smoking (5). The typical patient is a male who 
is young and smokes heavily and the use of or exposure to tobacco is of prime 
importance to the triggering or initiation and progression of this debilitating disease (3). 
Urinary levels of cotinine which is a major metabolite of nicotine, used as a measure of 
active smoking revealed a very close relation with Buerger’s disease (19). Both the 
decrease in prevalence of Buerger’s in the US among all patients and the increasing 
prevalence among females are attributed to a corresponding change in tobacco use. (5, 
15). 
There is a high prevalence noted in Southeast Asia among populations of low 
socioeconomic class who smoked bidis (a homemade surrogate for cigarettes, without 
filters from low quality tobacco.) These bidis contain more nicotine and toxic substances 
as compared to cigarettes. (18, 20).  Rahman et al compared  those who smoked more 
than 20 bidis per day to those who smoked less than 10 bidis per day and concluded that 
the odds ratio for developing TAO was significantly higher (58.28) in the former as 
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compared to the latter. (20).  Although a few researchers agree that Buerger’s disease can 
occur in non-smokers (21), most view exposure to smoke or a history of smoking present 
or past as essential for the diagnosis.(22) Harkavy was the first researcher to suggest the 
possibility of a hypersensitivity reaction to antigens present in  tobacco  in Buerger’s 
disease patients (6).  
           Cannabis consumption has also been noted more frequently in patients with TAO 
compared to controls. This may be because cannabis consumption is usually associated 
with smoking (23). 
 
 
Immune- mediated 
             Altered autoimmune responses could play a part in Buerger’s disease. 
Autoimmune phenomenon has been suggested because of the presence of high titers of 
anti-endothelial cell antibodies in patients with this disorder (24). Adar et al demonstrated 
that patients with the disease have an  elevated cellular sensitivity to type I and II 
collagen
 
(which is found in vascular smooth muscle) and elevated circulating antibodies 
to Type I and II collagen  as opposed to patients with arteriosclerosis obliterans or 
healthy males (25). An immune mediated endarteritis has also been suggested as 
immunochemical studies have demonstrated deposition of immunoglobulins and 
complement factors along the vascular elastic lamina in a linear fashion due to an antigen 
in the intimal layer.  T-cell mediated cellular immunity and B-cell mediated humoral 
immunity which along with the activation of macrophages or dendritic cells in the intima 
induces endarteritis within the vessel (26).  
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Endothelial dysfunction 
     Impaired peripheral endothelium-dependent vasodilatation has been documented in 
patients with Buerger's disease, while non endothelial mechanisms of vasodilatation seem 
to be unaffected (27). 
  
Genetic predisposition 
            De Moerloose et al discovered a significantly low frequency of the HLA-B12 
antigen among people with Buerger’s disease (2.2% vs. 28% in controls) implying a 
resistance gene (28).  Some researchers have noted an increased frequency of HLA-A9 
and HLA-Bw5 or HLA-B8, B-35 and B40 antigens in patients form Eastern European 
and Asian countries (4). Importantly the prevalence of Buerger’s disease is higher in 
Eastern Europe and Asia than in the US. Similar to many other autoimmune diseases, 
TAO may possibly have a certain genetic predisposition without a direct "causative" gene 
mutation. 
 
Hypercoagulability 
  A close association between thrombophilic diseases like antiphospholipid syndrome and 
hyperhomocysteinemia and Buerger’s disease is noted (29). TAO is also linked with a 
higher prevalence of anticardiolipin antibody (aCL). The presence of an n increased 
antibody titre among these patients is linked to increased morbidity especially major limb 
amputations (30).  
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Oral infection – inflammatory pathway. 
            Researchers have raised the possibility of an etiologic link between Buerger’s 
disease and long standing infections such as oral bacterial infections. Smoking, 
periodontitis and Buerger’s disease in certain studies have been shown to be linked. 
Smoking worsens periodontitis and it is postulated that it aggravates the oral infection. 
Using PCR, the bacteria found in the plaque was similar to that in the mouth with 
Treponema denticola, being present in most of the arterial specimens studied. and less 
commonly Campylobacter rectus and  Porphyromonas gingivalis (31).  
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Clinical Presentation  
The disease has often presented with symptoms of distal ischemia in a young male who is 
a heavy smoker with most common involvement of extremity arteries and less often non-
extremity arteries and nerves.  
 
Extremity arterial involvement 
                 This initiates with involvement of the smaller distal vessels of the lower limb 
and hands as a manifestation of infra-popliteal or infra-brachial occlusive disease, the 
lower limbs being much more commonly involved than the upper limbs.  Presenting 
symptom may be claudication, affecting the feet, legs, hands and arms, typically arch or 
forefoot and later calf. The pain which starts in the extremities could radiate to more 
central parts of the body (3). Trophic nail changes and ischemic ulcerations develop at an 
early stage in the natural history of the disease.  These are mostly found in the toes and 
fingers of the patient.  Critical limb ischemia (CLI) is manifested as ulcerations and 
digital gangrene with chronic ischemic rest pain. Upper extremities are involved in up to 
90% of cases unlike in atherosclerosis. Symptoms in upper limbs are similar to those of 
lower limbs in addition to Raynaud’s phenomenon (usually asymmetrical). 43% of 
patients may demonstrate involvement of all the 4 limbs. (4)  
 
Non-extremity arterial involvement 
              Non extremity arteries are not so commonly affected. Even and the coronary, 
mesenteric (32) and cerebral arteries (33) has been described to be involved.  Cases of 
aortic and even multiorgan arterial involvement have been described (34).  
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Gastrointestinal manifestations of the disease due to involvement of certain arteries 
supplying the gut have been rare and isolated.; however, intestinal symptoms and signs 
due to stricture or perforation of the colon may become apparent long before symptoms 
of severe peripheral arterial disease in patients with TAO (3).  If the smaller arteries are 
not involved it is highly unlikely for the larger arteries to be affected by the disease 
process.  Involvement of internal thoracic arteries and the coronary arteries without the 
involvement of extremity vessels has also been reported (35).         
    
Venous involvement                                                                                     
              Superficial thrombophlebitis is observed in 38% of patients with TAO (5).  This 
is a migratory thrombophlebitis or phlebitis saltans (without the presence of varicose 
veins) occurs as an early sign and can occur in 16 to 65% of patients who suffer from the 
disease. It predominantly affects small or medium sized veins in the feet, calves and 
forearms, and much less commonly the lesser or greater saphenous veins. The femoral or 
axillary vein involvement is a rarity. The lesions classically linear, but oft times may 
appear tuberous (4). Superficial thrombophlebitis is a clinical finding which differentiates 
Thromboangiitis obliterans from various vasculitides and atherosclerosis, though it may 
also be seen in Behçet's Disease. Superficial thrombophlebitis may predate the onset of 
ischemic symptoms due to the occlusive nature of the disease and often parallels disease 
activity (36).  
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Nerve involvement 
A thorough neurological examination may elicit a sensory deficit in up to 70% of patients 
(36). 
  
 
Physical examination 
                     A patient suspected to have Thromboangiitis obliterans should have a 
detailed physical and vascular examination. The peripheral pulses should be palpated. 
The radial, ulnar, dorsalis pedis or posterior tibial pulses may not be palpable.  
Auscultation, looking for arterial bruits, and measurement of the Ankle Brachial Pressure 
Index (ABI) should be performed.  A negative Allen’s test is highly suggestive of small 
vessel involvement in both the arms and the legs.  Although nonspecific, it assesses the 
circulation and uncovers arterial compromise of the upper extremity (37). In the early 
stage, involved vessels are indurated and tender, and bruits are usually not detected. 
Careful examination should be performed for dependent rubor, cyanosis, cold 
extremities, ulceration and gangrene.  The extremities should be examined carefully for 
superficial venous nodules and cords.  
 
Natural history 
               The disease process in TAO begins in the small foot and hand vessels and then 
progresses proximally. The progression may be in continuity or a new lesion may occur 
in a different segment of the arterial tree (skip lesions). In the majority of patients, the 
lesions do not extend proximal to the popliteal artery in the legs or the brachial artery in 
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the hands. The collateral circulation is found to usually be poor, and ischemic ulcerations 
of the toes and fingers develop at an early stage of the disease. 
                The disease waxes and wanes, with intermittent periods of active disease and 
acute exacerbation of symptoms which alternate with episodes of remission. The number 
of attacks may vary from one to twenty with the mean being 5.4 (38). The duration of 
remission may last up to years and may permanently subside if the patient stops smoking. 
Exacerbations are usually related to exposure to cigarette smoke. The virulence of the 
disease is maximum in the 3
rd
 to 5
th
 decade but may be lesser in older people as opposed 
to the temporal pattern than is seen in atherosclerosis. Shionoya didn’t report new ulcer 
formation in TAO affected individuals older than 60 years (4). Patients with Buerger’s 
disease very often are affected by severe ischemic pain and tissue loss which ultimately 
lead to minor and major limb amputation. In a study done by Cooper et al during a 15.6 
years of follow up of 111 patients the risk of any extremity amputation was 25%, 38% 
and 46% at 5, 10, and 20 years respectively. The risk of major amputation amounted to 
11%, 21% and 23% respectively (39).  But after cessation of smoking according to Olin 
et al only 2 out of 43 (5%) patients underwent amputation (5). Life expectancy is also 
reduced in patients with TAO (52.8 years) compared to that of matched US population 
(39).  
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Diagnosis 
Since there is no single confirmatory test to establish the diagnosis of TAO, a number of 
clinical signs and symptoms have been relied upon.  
 
Diagnostic criteria of Shionoya - 1998
   
(22)
       
 
• A history of smoking  
• Onset of symptoms before the age of 50 years; 
• Infrapopliteal arterial occlusions; 
• Either arm involvement or presence of phlebitis migrans; 
• Absence of atherosclerotic risk factors other than smoking. 
Diagnostic criteria of Olin - 2000 (2) 
• Age under 45 years; 
• History of recent/current tobacco use 
• The presence of distal-extremity ischemia indicated by claudication, pain at rest, 
ischemic ulcers or gangrenes and documented by non-invasive vascular testing; 
• Exclusion of autoimmune diseases, hypercoagulable states and diabetes mellitus; 
• Exclusion of a proximal source of emboli by echocardiography or arteriography; 
• Consistent arteriographic findings in the clinically involved and non-involved limbs. 
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Doppler ABI is a precise and affective method to document the presence and severity of 
lower extremity peripheral arterial occlusive disease. The most accurate studies are those 
which use objective methods of diagnosis, the Doppler being one of them.  An “ankle-
brachial index” (ABI)  is calculated by dividing the ankle systolic pressure measured with 
a blood pressure at the level of the malleolus by the higher of the two measured brachial 
pressures. An ABI which is greater than 1·0 is considered normal. It decreases to 0·50–
0·90 in patients presenting with claudication and to even lower levels in those patients 
who have pain at rest or tissue-loss (ulcers) (40). 
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Differential diagnosis 
The following differential diagnoses are to be considered for TAO. 
  Atherosclerotic PAD 
 Systemic vasculitis 
 Scleroderma 
 Emboli 
 Hypercoagulable states 
 CREST syndrome 
 Repetitive trauma 
 Drugs (ergot) 
           
 
Atherosclerosis is clinically distinguished from TAO by the very distal nature of 
involvement of vessels of the legs and arms in the latter. A negative Allen’s test in a 
young male smoker who presents with lower limb ulcerations is strongly suggestive of 
TAO (37). However, an abnormal result can also occur in certain other types of small 
vessel occlusive diseases of the upper limbs such as CREST syndrome, scleroderma, 
repetitive trauma, vasculitis, emboli and hypercoagulable states.  
 
The following features distinguish Buerger’s disease from atherosclerosis which has a 
similar clinical presentation. 
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Clinical Differences between Atherosclerosis and Buerger's Disease (4) 
Patient Characterestics                            Atherosclerosis               Buerger’s disease 
 
Age at presentation                                                 >40                                20-40 
History of tobacco use                                               +                                   ++ 
Other risk factors                                                         +                                   +/- 
Upper extremity involvement                                     -/+                                 +  
Proximal vessel involvement                                    ++                                 -/+ 
Migratory superficial thrombophlebitis                    -                                     + 
 
 
     ++   = invariably present;                     + = usually present;  
     +/-   = occasionally present;               -/+ = uncommonly present 
- = not a feature of the disease 
 
Laboratory tests 
               No specific test to diagnose Buerger’s disease is available. Laboratory tests are 
done to exclude alternative diagnoses. As opposed to other types of vasculitis, in patients 
with TAO, the acute phase reactions like Erythrocyte Sedimentation Rate or C - reactive 
protein level are usually within normal range (36). Occasionally an increased ESR, 
fibrinogen level and platelet count can be found in patients with tissue loss.  
              Other causes of vasculitis can be excluded by performing complete blood count, 
serum creatinine concentrations, rheumatoid factor, antinuclear antibody level, VDRL 
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antigen, liver function tests, serum complement levels (C1 – C4), serologic markers 
specific for CREST (calcinosis cutis, Raynaud’s phenomenon, sclerodactyly and 
telangiectasia) syndrome and scleroderma.  
              Hypercoagulopathies may be ruled out by performing Antithrombin III Level, 
Antiphospholipid antibodies, Factor V Leiden levels, Protein C level, Protein S level, and 
Prothrombin time and partial thromboplastin time. Anticollagen antibodies, 
Antiphospholipid and antielastin are occasionally found, although titres may be low (4).  
 
Pathology 
Histopathological specimens are obtained usually from amputated limb tissue or biopsy 
specimens from superficial inflamed veins. Findings are almost the same in the involved 
veins and arteries. Although no confirmatory histopathological features are established, 
the characteristics are unique for this disease to distinguish it as an entity very much 
distinct from conditions like atherosclerosis, necrotizing vasculitides or idiopathic arterial 
thrombosis.The findings are very likely to vary, depending upon the duration of the 
disease.   They have a high chance to be diagnostic if in the acute phase, a biopsy of a 
segment of a vein with superficial thrombophlebitis is done (2). 
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 Pathophysiological phases of Thromboangiitis obliterans (36) 
 
 
               The striking characteristic of Buerger's disease is the occlusive, highly 
inflammatory (cellular) thrombus with presence of microabscesses and multinucleated 
giant cells visualized within the thrombus during what is known as the acute phase (36).   
This thrombus is very different from the bland thrombus seen in hypercoagulable 
conditions. The vessel wall may show features of ongoing inflammation although to a 
much lesser extent. Segments of diseased arteries and veins are found to be present 
between segments of unaffected vessels in TAO as opposed to atherosclerosis where 
there is more diffuse arterial involvement (4).  Rarely few segments of blood vessels may 
also have a thrombus not infiltrated with the typical inflammatory cells seen in Buerger’s 
disease. The structure of the vessel wall is usually not altered, including the internal 
elastic lamina and media, a characteristic which firmly distinguishes TAO from 
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arteriosclerosis and from many other types of systemic vasculitis. There is no smooth 
muscle necrosis within the vessel wall or any evidence of fragmentation of the elastic 
lamellae: which is very often seen in necrotizing vasculitides.  
              If the disease has progressed to an intermediate phase (subacute) then 
organization of the thrombus which is progressive in nature within the arteries and the 
veins is seen. Finally in the end stage (chronic), an organized thrombus with fibrosis is 
seen within the vessels (3, 41).  In advanced stages of the condition, the lesions 
progressively become less distinctive. At this time an organized and re-canalized 
thrombus may exist. They thus provide a focal residual inflammatory reaction which may 
just be sufficient to suggest possible TAO (2).          
                 
                                             Other findings of note are onion shaped recanalizing of 
vessels in the involved arteries, adventitial fibrosis in the absence of medial fibrosis, 
endothelial swelling of the vasa vasorum and edema beneath the external elastic lamina 
(41). These findings would probably be helpful in coming to a differential diagnosis in 
patients with unusual clinical presentations. 
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Ultrasonography 
    Non-invasive vascular studies
 
are used to quantify and confirm the location and degree 
of peripheral arterial occlusive disease.  Aortic ultrasonography and echocardiography 
are helpful in ruling out a proximal embolic source. Duplex Ultrasonogram is another 
very useful tool.  
 
Corkscrew collaterals are classified into 4 types by artery amplitude and color Doppler 
flow formation pattern.  
 
Type I, large snake sign with an artery amplitude >5 mm being similar to or greater than 
amplitudes of original conduit arteries. 
 
Type II, small snake sign with an artery amplitude >3 and ≤5 mm, most of the corkscrew 
collaterals with an amplitude of ≤3 mm being shown as dot signs 
 
Type III, dot sign with corkscrew collaterals with an amplitude >1 and ≤3 mm shown as a 
striped pattern of the side row. 
 
Type IV, small dot sign with most of the corkscrew collaterals with an amplitude of ≤1 
mm shown as random points but not a striped pattern (42). 
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A: large snake sign                                 B: small snake sign 
                         C: dot sign with corkscrew collaterals   D: small dot sign 
 
 
 
      Arteriography is considered in patients in whom clinical features and ancillary 
laboratory studies fail to confidently establish the diagnosis. The findings that most 
characterize TAO are the following: smooth arterial walls of unaffected arteries, multiple 
peripheral segmental occlusions which are known as “skip lesions”.  Presence of direct 
corkscrew collateral vessels that follow the course of the involved/diseased vessel 
(Martorell’s sign) may be visualized. The collaterals represent the markedly enlarged 
vasa vasorum of the diseased vessel (43).  
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Characteristic angiographic Findings in Buerger’s Disease (4, 43) 
 
 Multiple segmental arterial involvement (skip lesions)                  100% 
 Smooth vessel wall in unaffected arteries                                       100% 
 Abrupt arterial occlusions                                                             42-100% 
 Smoothly tapered arterial occlusions                                            40-41% 
 Tortuous or corkscrew type collaterals                                            100% 
 Direct collaterals (Martorell’s sign)                                                     80% 
 “Tree root” or “spider leg” collaterals                                              40% 
 
                   The diagnostic value of many imaging methods such as computerized 
tomography (CT scan) and magnetic resonance imaging (MRI) in TAO still remains 
unclear. A proximal source of arterial embolism or a need to define the anatomy and 
extent of the diseases vessels may warrant an invasive contrast angiography or a CT or 
MRI. 
 
Management and Treatment 
The most important step in the treatment for TAO is smoking cessation. Even the use of 
one or two cigarettes per day or abuse of smokeless tobacco (chewing tobacco or using 
nicotine containing patches) has the potential to keep up the disease activity (44). 
Affected individuals who continue to smoke have been shown to be at risk for amputation 
of fingers and toes (3).  About   40% of these patients who are unable to quit smoking 
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require having a digit or extremity amputated, as compared to five percent of patients 
who abstain from smoking (5).   
         Supportive care is directed towards achieving the maximum blood supply to the 
diseased limbs as possible. Special caution is taken to avoid thermal, chemical or 
mechanical insult especially from poorly fitting footwear. 
                   Despite the important role of an inflammatory process in the pathogenesis of 
Buerger’s disease, anti-inflammatory agents e.g. steroids offer no benefit.  Although 
aspirin (acetyl salicylic acid) is often prescribed to patients, the real benefit of this or 
other oral anti-clotting drugs has not been demonstrated (3). Intravenous therapy with 
Iloprost (a prostaglandin analogue) is shown to be superior to aspirin in achieving pain 
relief. This drug has also been proven to be better in the healing of all trophic ulcers and 
reduces the risk of amputation (45). Medications such as clofibrate, (46)
 
cyclophosphamide, (47) and calcium channel blockers have been used with varying 
success. Other vasodilators, namely alpha-blockers or sildenafil, may be of some benefit, 
having not been evaluated sufficiently prospective clinical trials (36).  Induced 
hypervolemia and prostacyclins are effective in the treatment of critical limb ischemia in 
TAO.                              
                  In patients who are poor candidates for revascularization procedures due to 
the distal nature of their disease, augmentation of perfusion to the diseased limbs is 
achieved by the use of intermittent pneumatic compression of the foot and calves (48). 
The use of streptokinase given intra-arterially as thrombolytic therapy has been evaluated 
in patients with gangrene or pre-gangrenous lesions and has shown to be of some benefit 
(3). 
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          Surgical modalities include, arterial reconstruction, bypass vein grafts, lumbar 
symphathectomy, and when required, amputation.  Sympathectomy gives temporary pain 
relief and ulcer healing but no confirmed long term benefit. A laparoscopic method of 
sympathectomy has also been used (49). In patients with Thromboangiitis obliterans, 
surgical revascularization usually is not a feasible option because of the distal and diffuse 
nature of the condition. Bypass surgery may probably be considered in very select 
patients with CLI and suitable distal target vessels (36).  Neovascularization is one of the 
principles of treatment of chronic ischemia.  Both periosteal elevation and distraction 
osteogenesis have been shown to increase neovascularistion (50). 
                Newer modalities like microvascular omental transfer (51) and extended 
endovascular recanalisation (52) have been tried. Angiogenesis by autologous bone 
marrow mononuclear cell implantation (53) and gene therapy have shown promise.  
Experimentally, spinal cord stimulator and (VEGF) vascular endothelial growth factor 
have been used in patients with TAO (36).  However, the ideal modality for treatment of 
TAO is still undecided. 
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Lipoprotein (a) 
         Elevated Lipoprotein (a) or Lp (a) level has been reported to have a pathogenetic 
role, in atherosclerotic vascular disease and Thromboangiitis Obliterans. It was 
discovered half a century ago in 1963 by a Norwegian physician investigator Kare Berg 
(54). In 1987, the human gene which encoded this protein was cloned. Lipoprotein (a) is 
considered to be a vital molecule because its levels are genetically determined and have a 
very weak association with environmental factors, including the classically described 
vascular risk factors. 
Structure  
            It is a lipoprotein subclass which is made of an ordinary cholesterol rich LDL 
particle which is combined with an additional protein. Similar to LDL, the lipoprotein (a) 
particle contains Apolipoprotein B100 (512,000 D), but has an unusual structure in that it 
additionally consists of Apolipoprotein a (apo[a]) (275,000-800,000 D), which is 
covalently linked by a disulfide bond to apolipoprotein B100 (55).           
             Lp (a) exhibits remarkable size heterogeneity (56). Apo(a) is a large protein 
containing a series of amino acid repeats known as "kringles" containing 3 intrastrand 
disulfide bonds which are highly homologous to similar repeats found in the molecule  
plasminogen (11),   (75–85%  identical to the fourth kringle of plasminogen). There are a 
total of 11 apo(a) kringle sequences; ten of these are present as single copies, but the 
remaining 1(K4 type 2) varies in copy number which  is genetically determined and thus 
results in extremely high degree of inter-individual polymorphism in the molecular mass 
of apo(a). The kringle IV repeats may vary from 10 to >50, each of these variable kringle 
IV consisting of 114 amino acids (57).  These variable apo (a) sizes are known as "apo 
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(a) isoforms". The larger isoforms are compromised with respect to protein folding, 
transport, and secretion. Thus, the number of apo (a) KIV2 repeats is found to be 
inversely proportional to plasma lipoprotein (a) levels. 
Structure of Lipoprotein (a) 
 
 
Genetics of Apoprotein (a) 
               Lipoprotein (a) plasma concentrations are mainly controlled by the 
apolipoprotein (a) gene and highly heritable. [LPA is a large gene found on chromosome 
6q26-27 (adjacent to the plasminogen gene). The inter-individual variation in Lp (a) 
levels is 90% genetically determined by the LPA locus which determines heritability of 
plasma levels of the molecule (58). 
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                 Apo (a) proteins differ in mass predominantly due to size polymorphism [KIV-
2 VNTR], which is caused by the kringle IV repeats within the LPA gene. The 
genetically determined KIV2 repeat size has an effect on the final size of the apo(a) 
protein i.e. this size variation at the gene level is invariably expressed on the protein level 
also (11, 57). 
 
Synthesis and catabolism of Lp (a) 
    The liver cells (hepatocytes) express Apo (a) and the assembly of apo (a) and LDL 
particles probably take place at the outer hepatocyte surface.  The half-life of lipoprotein 
(a) in the circulation is about three to four days (59).  Until the precursor protein is 
released from the cell, Lipoprotein (a) is not fully synthesized; hence the rate of 
production of the larger isoforms is a limiting factor for the plasma concentration.  
              The sites and mechanisms of Lp (a) catabolism are not well understood.  A 
minor pathway of Lp (a) metabolism is uptake via the LDL receptor. The kidney has been 
found to play a role in Lipoprotein (a) clearance from plasma.         
 
Plasma levels of Lp (a) 
           In the general population plasma levels of Lipoprotein (a) have been found to 
range over 1,000-fold between individuals. And yet the plasma Lipoprotein (a) in a 
particular individual remains constant throughout his/her life from < 0.2 to > 200 mg/dL. 
This characteristic range of concentrations has been noted in all populations studied so 
far. In the study by Ashavaid et al from India, in normal subjects of both sexes, the 
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median level of Lipoprotein (a) was 12.9 mg/dl (60). Mohan et al reported a geometric 
mean of 19.4 mg/dl in healthy adults from South India (61). 
  
     
 
  Typical distributions of lipoprotein (a) levels in the general population : These graphs 
are based on non-fasting fresh serum samples from _3000 men and 3000 women from the 
Copenhagen General Population Study collected from 2003 through 2004.2 Green color 
indicates levels below the 80th percentile, whereas red color indicates levels above the 
80th percentile. 
 
When the mean concentrations between multiple world populations were studied, it was 
found interestingly that populations of African descent compared to Asian, Oceanic, or 
European populations had a 2-3 fold higher Lipoprotein (a) plasma concentration. (62). A 
large meta-analysis of 36 studies showed the median value of lipoprotein to be 12.6 
mg/dL. The blacks had a value more than 100% higher than that of whites (63). In all 
populations a general inverse correlation between apo (a) isoform size and Lipoprotein 
(a) plasma concentration has been observed; however, mean Lipoprotein (a) associated 
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with certain apo (a) isoforms varies between different populations. Sakurabayashi from 
Japan reported elevated Lp (a) levels to be one >30mg/dl (64). The Asians have higher 
serum concentrations of Lp (a) when compared to the general population in the United 
States (65) and the United Kingdom. This increase, found in indigenous Indians, is not 
affected by migration. Levels were almost twice as high in Indians as compared to 
Caucasians (12). 
Function & Pathophysiological role of Lp (a)  
The physiological or biochemical function of Lipoprotein (a)/apo (a) is not understood 
properly. People without Lp (a) or with very low levels of Lp (a) levels appear to be 
healthy. This indicates that plasma Lp (a) is certainly not vital to the cellular function 
under normal environmental conditions. Lp (a) could have a role with plasminogen 
activation or platelet function, or it could take part in the process of inflammation (66) or 
endothelial dysfunction (67). 
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PAI –Platelet Activation Inhibitor 1                   tPA – tissue Plasminogen  
Activator       uPA – Urine Plasminogen Activator 
                       
            Lipoprotein (a) has a role in thrombogenesis and atherogenesis. The 
pathophysiological effects of Lipoprotein (a) which includes those on fibrinolysis are 
probably due to apo (a) since it has a high degree of homology (similarity) to 
plasminogen, (11) a critical factor in the fibrinolysis system. Plasminogen, is the 
zymogen of the primary thrombolytic enzyme, plasmin. Plasminogen receptors are 
widely distributed on blood cells and are present at extremely high density on endothelial 
cells. These receptors promote thrombolysis by accelerating plasminogen activation
 
and 
protecting plasmin from inhibition. .By molecular mimicry, Lp (a) competes with 
plasminogen for receptors on cells, thrombolysis is inhibited and thrombosis promoted 
(68). 
           Lipoprotein's structure being similar to tissue plasminogen activator (tPA), it acts 
as a competitive inhibitor of tPA, thereby modulating the fibrinolytic system consistent 
with an atherogenic role (69).  In addition, since Lp (a) stimulates secretion of 
Plasminogen Activation Inhibitor-1 (PAI-1) it culminates in thrombogenesis. Besides, 
because it contains LDL cholesterol, Lp (a) definitely contributes to atherosclerosis (70) 
            Importantly Lp (a) has a role in transporting the more atherogenic pro-
inflammatory oxidized phospholipids which attract inflammatory cells to vessel walls 
(71) 
     
and leads to proliferation of smooth muscle cells. Endothelial cells play a key role 
in the initiation and propagation of the inflammatory response. One of the initial events in 
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atherogenesis is more binding of monocytes to endothelial cells and their entry into 
vessel walls.  Lp (a) enhances the expression of intercellular adhesion molecule (ICAM-
1) which supports the adhesion of various leukocytes including monocytes to the 
endothelial cell.  It is suspected that these monocytes have an important contribution to 
plaque formation (72). Apoprotein (a) has been found to have potential for atherogenicity 
and plaque formation. It also has a key role in thromboembolic events resulting from 
plaque rupture. 
    Other functions that have been described are related to recruitment of inflammatory 
cells which occurs by interaction with beta-2 integrin Mac-1 (73), angiogenesis, and 
wound healing. Another theory suggested by Linus Pauling, is that Lipoprotein (a) is an 
adaptation of primates to L-gulonolactone oxidase (GULO) deficiency which has been 
found only in certain mammals. GULO is necessary to convert glucose to ascorbic acid 
(vitamin C), which is in turn needed to repair arteries; following the loss of GULO, those 
primates which adopted diets that were less abundant in vitamin C may have used Lp(a) 
as an ascorbic-acid surrogate to repair their arterial walls (74). 
Lipoprotein (a) and cardiovascular disease         
               Lipoprotein (a) is considered as an important risk factor for cardiovascular 
diseases (75).    Its high concentration has been proven to be one of the major risk factors 
for premature development of diseases like atherosclerosis and cardiovascular disease (7, 
76). A similar risk associated with high Lp (a) levels has been reported by Beena et al 
from India (77).  The Copenhagen City Heart Study revealed a stepwise increase in risk 
of myocardial infarction with corresponding increase in levels of lipoprotein (a), with no 
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evidence of there being a threshold effect.  Extreme lipoprotein (a) levels predict a three 
to four fold increase in risk of myocardial infarction occurring in the general population 
(78). The largest epidemiological study till date on Lipoprotein (a) assessed the 
individual records of 126 634 participants in 36 prospective studies.  Lipoprotein (a) 
concentration was weakly correlated with the presence of several known vascular risk 
factors: strongly with total and non-HDL cholesterol, apolipoprotein B100. It was 
correlated inversely with loge triglycerides. Lipoprotein (a) levels were found to be 
twelve percent (95% CI: 8–16%) higher in women and eleven percent (4–17%) lower in 
people with diabetes (79).   It is also found to be an independent risk factor for CAD in 
Non-Insulin Dependent Diabetic patients in a study from South India (61). In a study by 
Bhavani et al from Hyderabad higher levels of Lp (a) was observed in patients with 
essential hypertension compared to controls (80).  High levels of Lp (a) has also been 
found in patients with stroke (8).  
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Lipoprotein (a), Peripheral Arterial Disease and Thromboangiitis Obliterans    
 
Majority of the research work investigating Lp (a) and peripheral arterial occlusive 
disease has been predominantly done upon Caucasian populations (75).  However, there 
are limited studies which specifically investigate Lp (a) and peripheral arterial occlusive 
disease in Asians or TAO in any population. In a report from Austria, patients with PAD 
had a significantly higher median level of Lp (a) compared to controls (76 v/s 47 mg/L) 
(81). In a study from Cambridge, UK, Lp (a) levels were measured in apparently healthy 
participants in the European Prospective Investigation of Cancer (EPIC)-Norfolk cohort, 
and the levels were associated with risk of PAD and CAD outcomes (82). The study by 
Hakim et al from Malaysia reported a significantly higher mean  level of Lp(a) among 
PAD patients compared to controls (0.56 v/s 0.29 g/L) (83) 
          Lipoprotein (a) levels have been found to correlate with Ankle Brachial Pressure 
Index (ABPI) and more severe forms of PAD. In a study among Chinese Type 2 diabetic 
patients, Lipoprotein (a) was found to be an independent risk factor for PAD. The optimal 
cutoff calculated was 13.3 mg/dl. Patients with Lp (a) above this value were found to 
have a 2.7-fold higher risk of PAD. Lp (a) also significantly increased from absence of 
PAD to mild and severe PAD (P < 0.001) (84).  
           A few sporadic cases of Thromboangiitis obliterans have been described in which 
elevated levels of lipoprotein (a) were reported (35, 85). A 39 year old woman with only 
involvement of the chest involving both coronary arteries and internal thoracic arteries 
was reported to have elevated lipoprotein (a) level. In this case the diagnosis was made 
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by the histological examination of the internal thoracic arteries discarded at surgery 
which showed thrombotic occlusion and characteristic intimal microabscesses with intact 
internal elastic lamina and tunica media (35). Biasi et al described a 35 year old male 
heavy smoker with Buerger’s disease who had high level of lipoprotein of 1010mg/L 
(normal <200) (85). Very high level of Lipoprotein (a) has been reported in a case of 
Buerger’s disease from Italy by Biasi et al almost two decades ago (13).  
            Kubo et al while investigating Lp (a) levels in CVD patients reported higher 
levels of Lp(a) in cases of Thromboangiitis obliterans (26.5mg/dl) compared to controls 
with risk factors (15.4mg/dl) and healthy controls (11.3mg/dl). (86). Takami et al from 
Japan conducted a study in male subjects to determine whether Lp (a) contributes to the 
marked increase in cardiovascular diseases without atherosclerotic lesions (10). Serum 
Lp(a) levels were measured  40-69 years old males with ischemic heart disease (IHD) 
with normal coronary angiogram (n = 35) and subjects with arteriosclerosis obliterans (n 
= 123) and IHD with atherosclerotic coronary lesion (n = 203) in addition to patients with  
Thromboangiitis obliterans (n = 40) and  healthy controls (n=156). The levels were 
significantly higher in all the groups compared to the controls.  The Lp (a) level of 
Thromboangiitis obliterans patients was found to be also much more elevated (21.3 
mg/dl) than that of the healthy control group (9.4mg/dl) (P < 0.05). 
 In a recent study on the prevalence of genetic and environmental vascular risk factors in 
non diabetic patients with premature peripheral arterial disease, either peripheral arterial 
occlusive disease or Thromboangiitis obliterans, the two main types of peripheral arterial 
disease, cases of peripheral arterial occlusive disease had  much more elevated levels 
(57.5mg/dl) compared to controls  (p value 0.02). But unlike in the previous reports, there 
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was no significant difference in the Lp (a) values between cases of Premature peripheral 
arterial disease and controls and also between TAO (32.5 mg/dl) and controls 
(25.7mg/dl). (23). 
         Raised levels of Lp (a) has also been seen with increased frequency in cases of 
Primary Antiphospholipid syndrome (87). 
 
 
Therapeutic considerations 
 
        A few studies have quoted a desirable serum level of Lp (a) of <50mg/dl and others 
have suggested < 30 mg/dL (75). Niacin has been shown to have an effect in reducing 
serum Lp (a) levels in coronary artery disease in a Caucasian population.  Combination 
therapy with neomycin (2 g/day) and niacin (3 g/day) in hyperlipoproteinemic subjects 
caused a 48% decrease in LDL cholesterol levels and a 45% decrease in the concentration 
of lipoprotein (a) thus altering the progression of cardiovascular disease (14). A meta-
analysis of the effect of nicotinic acid revealed a reduction in major coronary events by 
27% which could be attributable to decline in plasma LDL cholesterol and Lp(a) 
concentrations (88). Niacin can reduce lipoprotein (a) concentration in a dose dependent 
fashion by about 20-30%. In yet another study, it has been reported to decrease 
lipoprotein (a) concentration by 38% (89). Niacin acts by inhibiting Triglyceride 
synthesis in the hepatocyte, which causes an accelerated intracellular degradation of 
hepatic apo B and the reduced secretion of VLDL and LDL particles (90).       
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         A recent meta-analysis has suggested that atorvastatin may also lower Lp (a) levels 
(91). Similarly other uncommonly used molecules like acetylsalicylic acid and L-
carnitine as well as some medications in development including anti-sense 
oligonucleopeptides (mipomersen), and proprotein convertase subtilisin/kexin type 9 
(PCSK-9) inhibitors; Cholesterol-ester-transfer protein (CETP inhibitors) can reduce the 
elevated lipoprotein (a) concentrations. (92). The effect of estrogen on lipoprotein (a) 
levels is not well understood. Estrogen replacement therapy in many post-menopausal 
women suggests an association with lower lipoprotein (a) levels. Till date estrogen has 
not been indicated for treatment of elevated levels of lipoprotein (a). 
          Thyromimetics or Thyroid hormone analogs have also been tried to attempt to 
reduce levels of Lp (a). These thyroid hormones stimulate thyroid hormone receptors 
(TR) that have usually different tissue distribution and metabolic targets. TRβ is found 
predominantly in the liver. It has a major role in the metabolism of cholesterol and 
lipoproteins. TRα has its major role in fat, muscle, and the heart. Thyromimetics have 
been formulated which activate TRβ and are selectively taken up and/or activated by the 
liver. These molecules stimulate LDL receptors in the liver. They also induce cholesterol 
elimination as bile acids and cholesterol, and probably promote reverse cholesterol 
transport. In animals, they stop or slow down atherosclerotic progression. In humans, 
eprotirome, a thyromimetic has favorable lipid-modulating effects but lacks thyroid 
hormone-related side-effects. It also maintains normal hypothalamic-pituitary-thyroid 
feedback. When used in conjunction with statins, it decreases LDL and non-HDL 
cholesterol, apolipoprotein B, and triglycerides as well as lipoprotein (a) (93). It is not 
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clear whether the decrease in lipoprotein (a) reduction also points to reduced cardio 
vascular morbidity or mortality. 
                   In patients with vascular conditions, the effects of eicosapentaenoic acid 
(EPA) on serum lipoprotein (a) and other lipid levels were studied. The findings showed 
that long-term administration of EPA may reduce Lipoprotein (a) and serum lipids, which 
is of benefit for patients with various arterial occlusive diseases in terms of preventing 
progression of the disease.(94) Gingko biloba extract may be beneficial in cardiovascular 
high risk patients, but has not been clinically verified (95).  
                 Lipid apheresis causes excellent short term reduction of lipoprotein molecules 
and is indicated in cases, such as familial hypercholesterolemia, or treatment resistant 
hypercholesterolemia. (96). But this is extremely expensive and impractical for most 
other patients.  Niacin being the exception, the currently available drugs have minimal 
effect on lipoprotein (a) levels. 
              Currently, the recommended treatment for an elevated lipoprotein (a) in 
cardiovascular high risk patients is niacin, 1-3 grams daily, generally in an extended 
release form.   Aspirin may be beneficial as well. The goal of treatment is to achieve 
levels to below 50 mg/d (75). A similar recommendation is not available for management 
of patients with Thromboangiitis Obliterans. 
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MATERIALS AND METHODS 
 
           The study was conducted in Christian Medical College, Vellore in the department 
of General Surgery.  It was a case control study with cases defined as patients diagnosed 
to have Buerger’s disease according to Shionoya’s criteria.  The controls were all the 
patients admitted after the index case and who were under the age of 50 years and were 
matched for gender. The study period was from 1
st
 August 2011 to 30
th
 September 2013. 
This study was undertaken after obtaining Institutional Review Board approval. 
 
             Once a patient, either a case of Buerger’s disease or a control was recruited, 
informed consent was taken for collection of a fasting blood sample.  Every patient was 
given a patient information sheet which described the study and its purpose and benefits. 
A detailed history was taken and a thorough physical examination was done. History of 
smoking and its duration, and any drug intake, and previous operations were also noted 
down. All the peripheral pulses were documented.  Ankle Brachial Pressure Index and 
Toe Pressures and findings from imaging studies were documented.  
 
A fasting morning (6 AM) blood sample (2ml) was taken for estimation of Lipoprotein 
(a) levels.  The sample was immediately taken to the biochemistry laboratory and 
processed. The method used for estimation of lipoprotein (a) level was 
immunoturbidometry.   The analyzer used was a Roche p800 Modular.  The unit of 
measurement was mg/dL. 
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The data thus obtained was statistically analyzed. The cases and controls were compared 
for demographic data and lipoprotein values. The cases of TAO were categorized into 
different groups based on Lp (a) levels into those with <30mg/dl, and > 30 mg/dl. The 
groups were compared for severity of disease with Lp (a) levels. The statistical tests used 
were Pearson’s Chi square, T-test and Kruskal Wallis test. The level of significance was 
taken as a P value <0.05. 
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RESULTS AND ANALYSIS 
 A total of 45 patients each among Thromboangiitis patients (cases) and control groups 
were enrolled in the study. 
Table – 1 
AGE DISTRIBUTION AMONG CASES AND CONTROLS 
 
              AGE 
          (YEARS) 
           CASES 
               No. 
            CASES 
               % 
      CONTROLS 
           No. 
      CONTROLS 
              % 
            <25                 3               6.7               10              22.2 
           25-29                4              8.9                8              17.8 
          30-34                4              8.9                9             20.0 
          35-39                   9              20.0                5             11.1 
          40-44                9             20.0               8             17.8 
          45-49                9             20.0                5             11.1 
          >50                7             15.6                0               0 
         TOTAL              45             100                45            100 
                           
                         With Yates correction chi square= 11.179          df =6          p=0.082 Not significant (p>0.05) 
 
 
 Table – 1  (Fig- 1)shows the age distribution among study group and control groups. 
There were 3 cases (6.7%) of Thromboangiitis obliterans below 25 years of age, while 10 
controls (22.2%) were below 25 years. There was no statistically significant difference in 
the age groups between cases and controls. (p >0.05) 
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 Figure 1 
Age Distribution among Cases and Controls 
 
 
                                                                           Table – 2 
SEX DISTRBUTION  AMONG CASES AND CONTROL GROUPS 
 
               Males 
  No.                       % 
             Females 
     No.                  % 
 
Cases (n=45) 
 
 
  45 
 
      100 
 
   NIL 
 
       0 
 
Controls (n=45) 
 
   
45 
       
100 
    
NIL 
 
       0 
 
Table – 2 shows the sex distribution in this study.  All the 45 patients (100%)    among 
both cases and control groups were males. 
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Table – 3 
REGIONAL DISTRIBUTION OF CASES AND CONTROLS 
                                                                                            
 
                                 
                                       * p=0.035                            ** p=0.0193 
  
  Table – 3 (Fig-2, Fig-3) shows the regional distribution among cases and controls. 
Significantly more number of patients came from the eastern region, (55.6%) compared 
to the controls (31.1%), (p value 0.0193). Among cases and controls an equal number 
were from Bangladesh. Among the controls, the majority (60%) was from the south 
compared to patients with TAO (37.8%), (p value 0.035).  
Region Cases 
No. 
(%) 
Controls 
No. 
(%) 
 
South* 
 
17 
(37.8%) 
 
27 
(60.0%) 
 
West  
 
0 
 
1 
(2.2%) 
 
East** 
 
25 
(55.6%) 
 
14 
(31.1%) 
 
Bangladesh 
 
3 
(6.7%) 
 
3 
(6.7%) 
 
Total 
 
45 
(100.0%) 
 
45 
(100.0%) 
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Figure 2 - regional distributions of cases 
 
Figure 3 - Regional distribution of controls 
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Table – 4 
NUTRITIONAL STATUS AND CHRONIC DISORDERS 
 
 
              
   
Table – 4 shows the prevalence of malnutrition and chronic diseases such as diabetes and 
hypertension in the 2 groups. There was no statistically significant difference in the 
prevalence of any of these morbidities between the cases and controls.  
 
 
 
 
 
 
 
            Cases 
 No=45          % 
            Controls 
 No=45          % 
Pearson’s 
Chi sq 
P value 
 
Under 
nutrition 
 
 
7 
 
15.6 
 
3 
 
  6.7 
 
   1.800 
 
0.180 
 
Diabetes 
 
6 
 
 
13.3 
 
2 
 
  4.4 
 
    1.111 
 
0.292 
 
Hypertension 
 
5 
 
 
11.1 
 
1 
 
  2.2 
 
   1.394 
 
0.238 
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Table – 5 
ADDICTIONS AMONG CASES & CONTROLS 
 
           ADDICTIONS                     cases                    Controls 
        SMOKING* No=45 % No=45 % 
            Present 41 91.11% 4 8.89% 
            Absent 1 2.22% 41 91.11% 
            not known 3 6.67% 0 0 
 TOBACCO CHEWING** No=45 % No=45 % 
            Present 10 22.22% 3 6.67% 
            Absent 32 71.11% 42 93.33% 
            not known 3 6.67% 0 0.00% 
 
*X2 = 68.495, df = 1, p = 0.000                               ** X2= 5.023, df = 1, p=0.025 
 
Table – 5 shows the prevalence of smoking and tobacco chewing among the study group 
and control group patients. There was very highly significant increased prevalence of 
smoking among TAO cases (91.11%) compared to controls (8.9%)  (p value < 0.0001). 
Tobacco chewing was also significantly more common among patients (22.2%) than in 
controls (6.7%), (p value 0.025). 
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Table - 6 
Duration of smoking among patients with TAO 
 
Duration No. Percentage 
2-4.9 years 3 7.3% 
5-14.9 years 8 19.5% 
15-24.9 years 12 29.3% 
>25 years 13 31.7% 
Not Known 5 12.2% 
Total 41 100.0% 
 
Table –6  (Fig- 4) shows the duration of smoking in TAO patients. History of smoking 
for over 15 years was noted in 61% of the patients. Only a minority of cases (7.3%) had 
smoking history of less than 5 years. 
 
 
Figure 4 – The duration of smoking among patients of TAO (in years) 
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Table - 7 
PRESENTING SYMPTOMS & THEIR DURATION IN STUDY GROUP 
 
 
Symptom 
 
 
No. = 45 
 
Percentage 
 
Mean duration 
 
Claudication 
 
38 
 
 
84.4% 
 
35.9 months 
 
Rest pain 
 
27 
 
 
60.0% 
 
2.7 months 
 
Gangrene 
 
36 
 
 
80.0% 
 
8.7 months 
 
Ulcer 
 
20 
 
 
44.4% 
 
3.3 months 
 
 
          Table – 7 shows the prevalence and mean duration of symptoms in patients with 
TAO. Claudication of limbs was present in the majority (84.4%) of patients. Rest pain 
was observed in 60% of the patients and gangrene in 80%.    Claudication had the longest 
duration, mean value being 35.9 months. The symptom with the shortest duration was 
rest pain (2.7 months) 
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Table - 8 
PATTERN OF ARTERIAL INVOLVEMENT IN PATIENTS WITH TAO 
 
 
Arterial involvement 
 
No (45) 
 
 
Percentage 
 
Infrapopliteal 
 
14 
 
 
31.1% 
 
Femoropopliteal 
 
19 
 
 
42.2% 
 
Suprainguinal 
 
                  12 
 
 
26.7% 
 
Upper limb 
 
 
8 
 
17.8% 
 
 
The pattern of highest level of arterial occlusion is shown in Table 8 (Fig-5) . 
Infrapopliteal involvement was observed in 31.1% of patients. But when all cases (not 
only highest levels) are included this increased to 97.8% of cases.  Upper limb vessels 
were involved in 8 (17.8%) of patients. 
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Figure 5 
Pattern of vessel involvement in patients of TAO 
 
 
Table – 9 
LIPID PROFILE AMONG CASES 
 
 
LIPID 
 
mg/dl 
 
No=40 
 
Percentage 
 
Total cholesterol 
 
>160 
 
11 
 
27.5 
 
Triglycerides 
 
>150 
 
5 
 
12.5 
 
HDL cholesterol 
 
<40 
 
29 
 
72.5 
 
LDL cholesterol 
 
>100 
 
12 
 
30.0 
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Table -9 shows the prevalence of abnormal lipid profile in cases with TAO. Almost 3/4
th
 
(72.5%) of patients had low HDL cholesterol, while 27.5% had elevated total cholesterol. 
The mean Lp (a) for those with total cholesterol >160 mg/dl and <160 mg/dl was 64.4 
mg/dl and 61.7 mg/dl respectively and this difference was not statistically significant.  
 
 
Table -10 
ANKLE BRACHIAL PRESSURE INDEX & TOE PRESSURE AMONG CASES 
 
 
Measurements 
 
No. 
 
% 
ABPI 
 
<0.40 
 
10 
 
22.2 
 
0.41-0.90 
 
24 
 
53.3 
 
>0.9 
 
11 
 
24.4 
Toe pressure* 
 
<40 mmHg 
 
40 
 
88.8 
 
>40 mmHg 
 
4 
 
8.9 
 
Total 
 
45 
 
100.0 
*not done in 1 case 
 
The ankle brachial pressure index and Toe pressure in TAO patients is shown in Table –
10.  The index was less than 0.40 in 22.2% of the patients and between 0.4 and 0.9 in 24 
(53.35%) (Fig – 6).  Toe pressure of <40mmHg was seen in 88.8% of cases (Fig – 7). 
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                             Figure 6 - ABPI among cases 
 
 
 
                            Figure 7 -  Toe pressure among cases 
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Table – 11 
Frequency of normal & elevated Lp (a) values among cases and controls 
 
Groups <30mg/dl >30mg/dl Total 
 
Cases      count 
               % within group 
                % within Lp(a)   
 
 
12 
26.7% 
46.2% 
 
33 
73.3% 
51.6% 
 
45 
100.0% 
50.0% 
 
Controls  count 
               % within group 
             % within Lp(a) 
 
 
14 
31.1% 
53.8% 
 
31 
68.9% 
48.4% 
 
45 
100.0% 
50.0% 
                                           Chi square = 0.216                p value = 0.642 
 
Table – 11  (Fig – 8) shows the number of patients with normal (<30) and elevated Lp (a) 
(>30) values among the 2 groups of cases and controls. There was no significant 
difference between the 2 groups of cases and controls. 
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Figure 8 
Normal and elevated Lp(a) values among cases and controls 
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Table-12 
Lipoprotein (a) value categories in the cases and control groups 
 
 
Comparisons between 
Lp (a) <30 and 30-100 – chi square=0.09, p value = 0.764 
Lp (a) <30 and >100    - chi square =6.691    p value=0.0097 
Lp (a) 30-100 and >100 chi square = 8.954 p value = 0.0028 
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Table – 12 (Fig – 9) shows the frequency distribution of various categories of lipoprotein 
(a) levels among cases and controls. Values less than 30mg/dl were observed in 26.7% of 
study patients and 31.1% of the controls.  Very high values of Lp (a) were found only 
in TAO as compared to controls which was statistically highly significant (p=0.003). 
Very high values above 100mg/dl was seen in none of the controls, while it was 
observed in 10 patients with TAO (22.2%).                                                               
                                                             
 
                          Figure 9 -  Lp(a) categories among cases and controls 
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Table - 13 
Mean Lipoprotein values among the 2 groups of cases and controls 
 
Lp (a) Cases (mg/dl) 
 
Controls (mg/dl) 
 
Mean value 
 
70.194 
 
40.857 
 
Standard deviation 
 
69.425 
 
23.218 
 
Minimum value 
 
<3 
 
<3 
 
Maximum value 
 
354 
 
83.14 
 
   t value -2.688   p = 0.0086 
 
Table – 13 shows the mean lipoprotein (a) values among cases of TAO and the controls. 
The mean value of Lp (a) was significantly higher in cases of TAO (70.19) than in 
controls (40.86), (p value 0.0086).  The maximum level noted among the cases and 
controls were 354 mg/dl and 83.14 mg/dl respectively. The lowest value was <3mg/dl in 
both the groups. 
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Table -14 
Association of Lp (a) categories and presence of symptoms 
Lp(a) Claudication 
           No (%) 
Rest pain 
No (%) 
Gangrene 
No (%) 
Ulcer 
No (%) 
<30   
% within Lp(a) 
N=12 
 
10 (26.3%) 
 
83.3% 
6 (22.2%) 
 
50% 
9 (25%) 
 
78% 
6    (30%) 
 
50% 
 
30-100   
 % within Lp(a) 
N=23 
20 (52.6%) 
 
87% 
14 (51.9%) 
 
60.9% 
18 (50%) 
 
78.3% 
9    (45%) 
 
39.1% 
 
>100 
 % within Lp(a) 
N=10 
8 (21.1%) 
 
80% 
7 (25.9%) 
 
70% 
9 (25%) 
 
90% 
5    (25%) 
 
50% 
 
Total  
 % within Lp(a) 
N=45 
38 (100%) 
 
84.4% 
27 (100%) 
 
60% 
36 (100%) 
 
80% 
20   (100%) 
 
44.4% 
 
Chi Square 0.272 
 
0.924 0.856 0.538 
P value 
 
0.873 0.630 0.652 0.764 
 
Table – 14 shows the frequency distribution of Lp (a) categories and the presenting 
symptoms. There was no significant difference in the number of patients with any 
symptom across various categories of Lp (a) (p=>0.05). 
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Table -15 
Relationship between Mean duration of symptoms, 
 Claudication distance and L p (a) values 
 
Lp(a) Values 
      (mg/dl) 
Claudication 
duration 
(months) 
Claudication 
distance 
(meters) 
Rest pain 
duration 
(months) 
Gangrene 
duration 
(months) 
Ulcer 
duration 
(months) 
<30 45.8 136 3.9 12.4 2.3 
30-99 42.0 358 2.75 3.97 4.08 
>100 6.7 129 1.7 14.1 2.7 
Total cases 35.9 253 2.7 8.7 3.3 
Kruskal-Wallis test 
Significance (<0.05) 
0.201 0.069 0.242 0.588 0.392 
  
Table – 15 shows the mean duration of symptoms and claudication distance in various 
categories of lipoprotein values.  Kruskal-Wallis test for independent samples did not 
show any significant differences in the duration of symptoms or claudication distance 
across the various categories of Lp (a) (p>0.05). 
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Table-16 
 Association between ABPI and Lipoprotein values  
 
ABPI 
Lipoprotein values (mg %) 
<30 30-100 >100 
<0.40 1 
(8.3) 
6 
(26.1) 
3 
(30.0) 
0.40-0.90 8 
(66.7) 
13 
(56.5) 
3 
(30.0) 
>0.90 3 
(25.0) 
4 
(17.4) 
4 
(40.0) 
                                             Chi square = 4.393                          p value = 0.355 
Table – 16 (Fig – 10)  shows the association between ABPI and lipoprotein (a) values. 
There was no significant difference between rising ABPI values and the various 
categories of Lp (a) (p value = 0.355).                                                       
 
 
Figure 10 
Ankle Brachial Pressure Index & Lp(a) categories among cases 
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Table -17 
 Toe Pressure & Lp (a) levels among Cases* 
Toe pressure 
mmHg 
Lp(a) <30 mg/dl Lp(a) 30-100 mg/dl Lp(a) >100 mg/dl 
<40 12 
(100%) 
21 
(91.3%) 
7 
(77.8%) 
>40 0 
(0%) 
2 
(8.7%) 
2 
(22.2%) 
*Not done in one case 
Yates correction, Chi square=1.065        p value=0.587   
Table – 17 (Fig -11) shows the association of toe pressure with Lp (a) levels. There was 
no significant difference in the toe pressure in the 2 groups with increasing levels of 
Lp(a).      
   
 
Fig 11 
Toe pressure & Lp(a) values 
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Table 18 
Pattern of vessel involvement and Lp (a) values 
Vascular involvement <30 
 
>30 
 
Total 
 
 X2 P value 
Infrapopliteal (IP) 
    % of vascular 
    % of Lp(a) 
3 
(21.4%) 
(25%) 
11 
(78.6%) 
(33.3%) 
14 
(100%) 
(31.1%) 
IP v/s 
FP 
 
 
IP v/s 
SI 
 
 
IP v/s 
UL 
 
 
FP v/s 
SI 
 
 
FP v/s 
UL 
 
 
SI v/s 
UL 
 
0.416 
 
 
0.132 
 
 
1.127 
 
 
0.278 
 
 
0.654 
 
 
0.99 
0.680 
 
 
0.896 
 
 
0.273 
 
 
0.783 
 
 
0.519 
 
 
0.333 
Femoropopliteal(FP) 
   % of vascular 
   % of Lp(a) 
6 
(31.6%) 
(50%) 
13 
(68.4%) 
(39.4%) 
19 
(100%) 
(42.2%) 
Suprainguinal (SI) 
   % of vascular  
   % of Lp(a) 
3 
(25%) 
(25%) 
9 
(75%) 
(27.3%) 
12 
(100%) 
(26.7%) 
Upper limb (UL)* 
   % of vascular 
   % of Lp(a) 
2* 
(25%) 
(16.7%) 
6* 
(75%) 
(18.2%) 
8* 
(100%) 
(17.8%) 
 
Total  
   % of vascular 
   % of Lp(a) 
12 
(26.7%) 
(100%) 
33 
(73.3%) 
(100%) 
45 
(100%) 
(100%) 
 
*Cases with UL involvement had in addition lower limb involvement 
 
 
Table – 18  (Fig – 12) shows the pattern of vessel involvement in various categories of 
lipoprotein values. There was no significant difference between any of the groups with 
regard to the level of vascular involvement and Lp (a) values (p=>0.05)  
71 
 
Figure 12 
Pattern of vascular involvement and Lp(a) levels 
 
Table - 19 
TREATMENT MODALITIES AMONG CASES 
                                      TREATMENT n=45 Percentage     Mean 
Lp(a) 
P 
value 
Conservative 12 26.67 66.34 0.78 
Single procedure 22 48.89 50.5 0.054* 
Multiple  procedures 11 24.44 113.7 
Lumbar sympathectomy 12 26.67 90.55 0.245 
Angioplasty & Stenting   5 11.11 33.72 0.0092 
 
Surgical 
Amputation 13 28.89 120.81 0.0148 
Bypass 11 24.44 55.12 0.303 
Miscellaneous   6 13.33 93.71 0.333 
*comparison between single and multiple procedures. 
    
 Table -19 shows the various modalities of treatment offered to the patients in the study 
group. Conservative therapy was carried out in 12 (26.7%) patients. Eleven patients 
(24.4%) had multiple surgical procedures. Amputation was performed in 13 (28.89%) 
and bypass surgery in 11 (24.44%) patients.  Patients who underwent amputation had 
significantly higher level of Lp (a), p=0.0148. Patients who had single procedure had 
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lower mean level of Lp (a) compared to those who had multiple procedures (50.5mg/dl 
versus 113.7mg/dl), though statistically the difference was not significant (p=0.054).       
                                                            
Table -20 
Risk of amputation among Lp (a) level categories 
 
Lp(a) values 
    (mg/dl) 
Amputations done Amputations not done  
Total No % No % 
<30 1 8.3% 11 33.3% 12 (26.7%) 
>30 12 91.7% 21 66.7% 33 (73.3%) 
                                          Chi square = 2.139                      p= 0.144 
Table -20  (Fig - 13) shows the risk of amputation among those with normal levels 
compared to those with abnormal levels of Lp (a). There was no significant difference 
between the 2 groups. 
 
Figure 13 - Amputation and Lp(a) levels 
 
0 
5 
10 
15 
20 
25 
<30 >30 
N
u
m
b
e
r 
o
f 
ca
se
s 
Lp(a) levels in mg/dl 
Amputation done 
Amputation not done 
73 
Table-21 
RISK OF AMPUTATION AMONG CATEGORIES OF LP (a) VALUES 
 
             Lp(a) values 
               (mg/dl) 
Amputations 
No % 
<30   ( n=12)* 1 8.3% 
30-100  (n=23)** 5 21.7% 
>100 (n=10)*** 7  70.0% 
           
 
           Pearson’s Chi square =11.268                  p value = 0.004 
             Comparison between * & ** chi square=0.277, p = 0.599 
             Comparison between * & *** chi square=6.497,   p=0.011 
          Comparison between ** & *** chi square=5.085, p=0.024 
 
 
Table – 21 (Fig -14) shows the risk of amputation in relation to various categories of Lp 
(a) values. It was 70% in those with Lp (a) levels above 100mg/dl, significantly more 
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than in those with lesser values (p=0.004). 
 
Fig 14 - Risk of amputation and Lp(a) categories 
 
Table - 22 
Mean Lp (a) values among amputees and non-amputees                                                
 Mean value of Lp(a) Std deviation  Significance value 
Amputation done 120.82 49.63 T value = 2.75 
P = 0.0148 Amputation not done 49.63 48.28 
 
Table – 22 shows that the mean Lp (a) value was significantly higher in the amputees 
compared to the non-amputees (p=0.0148). 
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Summary of Results 
A total of forty five cases and forty five controls were recruited for the study and their 
serum lipoprotein (a) levels were measured.  
30 mg/dL was taken as the normal cutoff.  
The levels of Lp (a) were not found to be significantly higher in the cases as compared to 
controls (p value = 0.642) .   
When Lp(a) levels were categorized into 3 groups <30mg/dl, 30-100mg/dl and 
>100mg/dl, there was significantly more cases with higher values compared to controls. 
This can be attributed to the very high values  (>100mg/dl) found only in the patients 
with TAO and not amongst controls.  
Importantly,  the mean value in the cases was significantly higher (70.19mg/dl) than in 
the controls  (40.86mg/dl) (p value 0.0086).  
There was no association between duration of symptoms like claudication, rest pain, 
gangrene and ulcer and Lp(a) levels. (p 0.201, 0.242, 0.588 and 0.392) 
There was also no association found between ABPI and Toe Pressures and levels of Lp(a) 
p value = 0.642)  and between pattern of vascular involvement Lp(a) levels.  
Another point of interest was that patients who had very high values of lipoprotein (a) 
(>100mg/dl) had a significantly higher risk of amputation (p=0.011). 
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DISCUSSION 
Thromboangiitis obliterans (TAO) is a segmental, recurrent, inflammatory, obliterative 
vascular disease involving medium-sized arteries and veins of the limbs characterised by 
thrombosis and recanalisation of the involved vessels. 
 
The majority of the patients (64.4%) were under 45 years of age (Table – 1). There was 
no significant difference in the frequency distribution of various age groups among cases 
and controls (p >0.05).  The mean age in our study was 41 + 10 years, very similar to that 
by Olin et al in which the mean age was 42 +  11 years.(5) Our findings are comparable 
to the diagnostic criteria of Olin (2) where the age is predominantly under 45 years and 
Shionoya (22) in which the age is under 50 years. But in the report by Matsushita et al the 
mean age was slightly lower (36 + 8 years) (16) and in the study by Cooper et al it was 
even lower (33 years + 8) (39).  
 
      All the patients were males in our study (Table – 2) which is similar to literature 
reports in which males represent over 90% of affected cases (4) and in a report from 
Japan 96% of cases were found to be males (16).  A rising trend in women has been 
reported which is attributed to the increased prevalence of smoking in women (15). 
  Table – 3 shows the regional, distribution of cases.  Majority of our patients were from 
the east, 55.6% from eastern region of India and 6.7% from an eastern country, 
Bangladesh. This is again similar to what has been described previously, where the 
highest incidence is seen in the Far East (3). Another reason could be that our institution 
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is a preferred centre for tertiary care by the patients from eastern India especially West 
Bengal.  
          The prevalence of under nutrition and chronic diseases like diabetes and 
hypertension were similar in the cases and control groups (Table-4- ). Hypertension was 
observed in 5 (11.1%) of patients with TAO. Cooper et al reported 8.1% of patients with 
hypertension (39).  There was very highly significant increased prevalence of addictions 
among the cases compared to the controls (Table – 5). Smoking was observed in 91.1% 
and 8.9% among cases and controls (p value 0.0000). Similarly tobacco chewing was also 
significantly more among cases, (p vale 0.025). This is in accordance with the known fact 
of a strong link between tobacco consumption and disease (22), and the typical patient 
being a heavy smoker and tobacco consumption being central to the initiation and 
progression of the disease (3). Even without smoking, tobacco chewing itself is a risk 
factor for the development of Thromboangiitis obliterans (36).  
         Table – 6 shows the duration of smoking among the cases, majority were chronic 
smokers, 61% having smoked for over 15 years. Our study is consistent with the 
extremely strong association between heavy use of tobacco and TAO (2).  
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 In the current study (Table – 7), the commonest symptom was claudication observed in 
84.4% of patients, higher than that reported by Szuba et al, varying from 18% to 63% (4). 
In the study by Malecki et al, claudication was observed in 44% of patients. Gangrene 
and ulcer were noted in 80%, and 44.4% respectively.  This is much higher than that 
reported by Malecki et al from Poland (7%) (38) but this is comparable to 50-81% 
reported by Szuba et al (4). Rest pain was observed in 60% of our cases compared to the 
study by Olin et al where it was 76% (5). But Malecki et al reported a much lower 
incidence of 9% rest pain in cases of TAO (38). At presentation the longest duration was 
for claudication (mean 35.9 months) and the shortest for rest pain (2.7 months) and non 
healing ulcer (3.3 months). This is because pain even at rest which is indicative of critical 
limb ischemia motivates a patient to seek treatment from a tertiary care centre.  
            The pattern of arterial involvement at the highest level is shown in Table -8. 
Infrapopliteal involvement was seen in 31.1%, and upper limb involvement in 17.8% 
cases in our study. This is lower than other reports where lower extremity involvement 
was reported in 46% by Olin et al (5). Malecki et al have reported 100% affection of 
lower limbs irrespective of involvement at a higher level. (38). This is similar to our 
findings of 97.8% involvement when all levels are considered.  Upper limbs were 
involved in 17.8% of our patients which is lower than 44% reported by Malecki et al 
(38).  
Infra popliteal involvement has been reported in 90 -100% of patients in literature (4). 
Upper limb involvement has been higher 38% as reported by Mills et al (97) and 50% 
among affected women in the study by Lie (15). Malecki et al has reported 100% of 
lower limb involvement and 44% of upper limb involvement (38). 
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        An Ankle Brachial Pressure Index of 0.40 or less, which is considered as a marker 
of critical limb ischemia by  the American Diabetes Association was observed in 10 
(22.2%) of cases (Table – 10) (98). 
Table – 11 which shows the frequency distribution of normal and elevated levels of Lp 
(a) showed no significant differences between cases and controls.  But as shown in Table 
– 12 when those with Lp(a) levels above 30mg/dl were classified further into those above 
100mg/dl and those between 30 to 100mg/dl, there was a significantly more number of 
cases with elevated levels than controls. (p= 0.003). This implies that patients with 
markedly elevated serum lipoprotein (a) levels are more likely to be at risk of developing 
TAO. The frequency of markedly elevated lipoprotein (a) level is 22.2% in this study. 
This can be compared to the study by Murase et al where markedly elevated Lp(a) levels 
had an impact on the risk of CAD and the frequency was 6.4% in cases of familial 
hypercholesterolemia and 0.9% in diabetes (99). 
          The mean lipoprotein(a) value of the cases (70.19) was significantly higher than 
that of the controls (40.86), p value 0.0086 as shown in Table – 13, which is similar to 
earlier reports (17, 86). According to Takami et al, the level observed was 23.1mg/dl in 
their patients with TAO, but this is much higher in our study (17).  In the report by Kubo 
et al the Lp (a) levels in TAO patients was 26.5 mg/dl as against 15.4 mg/dl in controls. 
This again is much lower than what has been observed in this study. The highest level 
noted in our study was 354mg/dl which is three times higher than the level of 1010mg/L 
(101mg/dl) which has been reported in a case of Buerger’s disease from Italy (85). 
According to Nordestguard et al, lipoprotein (a) level may vary up to a 1000 fold even in 
normal individuals (100). 
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    A high level of total cholesterol >160mg/dl and LDL-cholesterol >100mg/dl was 
observed in 27.5% and 30% of patients respectively (Table -9). But Cooper et al observed 
hyperlipidemia in a greater proportion (46.5%) of cases with TAO (39). There was no 
significant difference in the mean Lp (a) levels of patients with high and normal total 
cholesterol levels in the current study. But in a study from Taiwan there was a significant 
association of total cholesterol and LDL cholesterol with serum Lp (a) levels (101). 
The prevalence and duration of symptoms of claudication, rest pain, gangrene and ulcer, 
had no significant association with the Lp (a) values. (Table-14 & 15). ABPI and Toe 
pressure measurements also did not have any association with serum Lp (a) values (Table 
– 16, 17). Both ABPI and Toe pressure which are measures of severity of arterial 
occlusion showed no association with Lp (a) levels. These probably indicate that that 
there is no association between severity of disease as measured by ABPI and Toe 
pressures, and serum Lp (a) levels.  The pattern of vessel involvement did not reveal any 
relationship with Lp (a) levels (Table – 18).  
       Conservative management and lumbar sympathectomy were done in 12 patients each 
(26.7%). Bypass was performed in 11 (24.4%) and amputation in 13 (28.9%). Mills et al 
reported an incidence of 31% for amputations (97). In the study by Cooper et al, the risk 
of any extremity amputation was 25% at 5 years (39). Major amputation defined as 
above-the-knee, below-the-knee or hand amputation was performed in 4 patients (8.89%) 
in our series. The rate of major amputation was 3.9% in the study by Ohta et al (102).   
According to the report by Cooper et al, the risk of major amputation at follow-up 
at 5 years, 10 years and 20 years was 11%, 21% and 23% respectively among TAO 
patients who continued smoking (39). After smoking cessation only 2 out of 89 (2.2) 
81 
underwent amputation according to the study by Olin et al (5). The mean Lp (a) value 
was significantly higher in those undergoing amputation, 120.81 mg/dl versus 49.63 
mg/dl (p value 0.0148). With rising Lp (a) levels there was increasing risk of amputations 
(table – 20) (p value 0.00275). This is suggestive of an association between severity of 
disease and the Lp (a) levels. 
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LIMITATIONS OF THE STUDY 
The exact role of lipoprotein in thrombogenesis is not well understood. It may well be an 
inflammatory marker in chronic diseases.  
The population studied may not be representative of the country.  Most of the cases were 
from the eastern region.  
The role of smoking on lipoprotein cannot be commented upon as smoking was not taken 
into consideration for choosing controls. 
The sample size calculated is very small. 
The acceptable level of lipoprotein (a) has been debated and there is no agreed upon 
“normal value”. In our study it has been taken as < 30 mg/dL.  Other studies say a value 
of less than 50 mg/dL is the target. 
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